SETDB1 and colorectal cancer: Similarly, in colorectal cancer, overexpression of SETDB1 promotes cell proliferation by activating AKT, while inhibition of SETDB1 enhances cetuximab sensitivity in colorectal cancer therapy (Hou et al., 2020).